Le Lézard
Classified in: Health, Science and technology

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on January 18, 2022 the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit award covering 11,250 shares of Puma common stock to one new non-executive employee.

The award was granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit award vests over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award's vesting commencement date, January 1, 2022, and one-sixth of the shares underlying the award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The award was granted as an inducement material to the new employee entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

These press releases may also interest you

at 08:25
The "21 CFR Part 11 Compliance for SaaS/Cloud Applications" training has been added to ResearchAndMarkets.com's offering. This highly interactive two-day course uses real-life examples and explores proven techniques for reducing costs, usually by...

at 08:25
DigitalOcean Holdings, Inc. , the cloud for developers, startups and SMBs, today announced that its board of directors has approved a new plan for the repurchase of up to an aggregate of $300 million of its common stock. This plan is in addition to...

at 08:25
The "Urban Planning and Design Software Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Component, Deployment and Application" report has been added to ResearchAndMarkets.com's offering. Increasing Adoption of Cloud-Based Software...

at 08:22
BlockTrust, a trusted authority for NFT marketplaces and a world leader in web3, blockchain technology and token utility, collaborates with Australia's largest theme park and entertainment operator, Village Roadshow, to launch a blockchain-powered...

at 08:20
Nova Credit, the fintech unlocking opportunities for mainstream and credit-excluded consumers and the companies looking to serve them, announced a partnership with Alloy, the leading identity decisioning platform for banks and fintech companies. The...

at 08:20
Avaya , a global leader in solutions to enhance and simplify communications and collaboration, today announced five U.S. and four Canadian partners who have been honored for their outstanding collaboration, contribution, and commitment to...

News published on 20 january 2022 at 17:10 and distributed by: